Is International Journal of Biological Macromolecules a Good Journal? Reputation, Fit and Who Should Submit

IJBM's 8.5 impact factor puts it in the top quartile for biochemistry journals. That's higher than Proteins (3.5), comparable to Biomacromolecules (6.2), and well above Journal of Biochemistry (2.8). For applied protein science, it's genuinely competitive.

The International Journal of Biological Macromolecules Impact Factor 2026: Ranking, Quartile & What It Means ranking reflects its position as a primary venue for functional macromolecule research.

The 45-55% acceptance rate is moderately selective. This isn't a journal that accepts everything, but it's not brutally competitive either. Most rejections happen at the editorial stage when papers lack sufficient functional characterization or fall outside the scope.

For context, Biomacromolecules has a similar acceptance rate but focuses more on synthetic polymer chemistry. IJBM skews toward biological applications and natural macromolecules, which explains why protein engineering papers often find a better fit here than in purely synthetic polymer journals.

The competitive landscape for macromolecule research splits along several lines, and IJBM occupies a specific niche that's worth understanding before you submit.

Against Proteins: Structure, Function, and Bioinformatics, IJBM is less focused on pure structural biology and more interested in engineered function. Proteins publishes excellent crystallography and NMR studies even when the biological relevance isn't immediately clear. IJBM wants to know what the protein actually does and why that matters for applications. If you've solved a structure and characterized function, you could go either way. If you've only solved the structure, Proteins is the better choice.

Biomacromolecules overlaps significantly with IJBM but has different editorial priorities. Biomacromolecules emphasizes synthetic polymer chemistry and materials properties. IJBM prefers biological macromolecules and biomedical applications. A paper on synthetic polymer drug delivery vehicles might fit either journal, but IJBM would want more biological characterization while Biomacromolecules would accept stronger materials characterization with minimal bio data.

The prestige question matters here. In protein engineering circles, IJBM is well-regarded for applied work. For basic structural biology, it's not the first choice. Materials scientists often view Biomacromolecules as more rigorous for synthetic work, while biochemists see IJBM as more relevant for natural macromolecules.

Journal of Biochemistry covers broader biochemistry with lower selectivity and impact. If your macromolecule work doesn't fit IJBM's applied focus, J. Biochem might accept it, but you're trading impact factor for acceptance probability.

Speed varies significantly. IJBM typically takes 90-120 days from submission to decision, which is standard for Elsevier biochemistry journals. Proteins can be faster (60-90 days) but rejection rates are higher. Biomacromolecules runs similar timelines to IJBM but with more demanding reviewer requirements for materials characterization.

The practical choice often comes down to your primary field identity. Protein engineers who want to reach biomedical applications researchers should consider IJBM. Structural biologists should think Proteins. Materials scientists developing biomedical polymers should consider Biomacromolecules unless the biological characterization is extensive.

IJBM typically takes 90-120 days from submission to first decision, which is standard for Elsevier biochemistry journals. Initial editorial screening happens within 7-14 days, and papers that pass editorial review go to 2-3 reviewers.

Most delays occur during reviewer selection. Finding qualified reviewers for interdisciplinary macromolecule work can be challenging, especially for papers that span protein engineering and biomedical applications. Be patient if your review process extends beyond 120 days.

Revision turnaround is usually faster, with decisions on revised manuscripts typically within 4-6 weeks. The editors are generally reasonable about revision requests and will work with authors who address reviewer concerns thoroughly.

Protein engineers working on biomedically relevant applications should strongly consider IJBM. If you've developed enzyme variants with improved therapeutic potential, engineered protein-protein interactions for drug targets, or created protein-based biomaterials, this journal is designed for your work.

Polysaccharide researchers with functional data belong here. Studies on chitosan derivatives with proven antimicrobial activity, modified cellulose for controlled drug release, or alginate systems that enhance cell growth all fit the editorial scope perfectly.

Biomedical polymer scientists who've done the biological characterization work will find a receptive audience. Papers on polymer-drug conjugates with pharmacokinetic data, hydrogels with cell compatibility studies, or surface modifications with demonstrated biocompatibility improvements align well with editorial priorities.

Researchers bridging materials science and biology should consider IJBM when their biological characterization is extensive. If you've spent as much effort on biological validation as materials characterization, you're probably in the right place.